文献速递瓣膜病与结构性心脏病

TAVI后自体主动脉瓣病变进展与生物瓣退化

Native Aortic Valve Disease Progression and Bioprosthetic Valve Degeneration in Patients With Transcatheter Aortic Valve Implantation.
PubMed 文献 · Circulation · 2021-08-29

多中心横断面观察队列研究对47例TAVI与51例生物瓣SAVR患者行超声、CT及18F-NaF PET/CT成像并随访超声。TAVI后保留的自体主动脉瓣仍存在活动性病变,生物瓣退化程度与SAVR相近,提示中期耐久性相当。

要点

  • TAVI后自体主动脉瓣仍可见持续活动性病变
  • 生物瓣退化程度TAVI与SAVR相当
  • 18F-NaF摄取可预测主动脉瓣峰值流速进展

核心结论

  • TAVI患者保留的自体主动脉瓣存在持续活动性病变证据;各成像方式显示TAVI生物瓣退化程度与SAVR相近,提示中期耐久性相当。

研究设计与样本

  • 多中心横断面观察队列研究;TAVI患者n=47(1个月9例、2年22例、5年16例),匹配生物瓣SAVR患者n=51,均行超声、CTA及18F-NaF PET/CT并后续系列超声随访。

主要发现

  • TAVI患者自体主动脉瓣在生物瓣外侧显示18F-NaF摄取,与TAVI后时间呈弱相关(r=0.36,P=0.023)。
  • 生物瓣叶18F-NaF摄取SAVR与TAVI相当(靶本比1.3[1.2-1.7]对1.3[1.2-1.5],P=0.27)。
  • 基线生物瓣退化影像证据频率:超声6%对8%(P=0.78)、CT 15%对14%(P=0.87)、PET 15%对29%(P=0.09)。
  • 基线18F-NaF摄取与后续峰值主动脉流速变化相关:TAVI r=0.7(P<0.001),SAVR r=0.7(P<0.001)。
  • 多变量分析中18F-NaF摄取是峰值流速进展的唯一预测因素(P<0.001)。

临床怎么用

  • TAVI术后应关注保留自体主动脉瓣的病变活动,并可用18F-NaF PET评估生物瓣退化风险。
  • 18F-NaF摄取与峰值流速进展相关,可作为随访瓣功能恶化的影像标志物参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Major uncertainties remain regarding disease activity within the retained native aortic valve, and regarding bioprosthetic valve durability, after transcatheter aortic valve implantation (TAVI). We aimed to assess native aortic valve disease activity and bioprosthetic valve durability in patients with TAVI in comparison with subjects with bioprosthetic surgical aortic valve replacement (SAVR). METHODS: In a multicenter cross-sectional observational cohort study, patients with TAVI or bioprosthetic SAVR underwent baseline echocardiography, computed tomography angiography, and 18F-sodium fluoride (18F-NaF) positron emission tomography. Participants (n=47) were imaged once with 18F-NaF positron emission tomography/computed tomography either at 1 month (n=9, 19%), 2 years (n=22, 47%), or 5 years (16, 34%) after valve implantation. Patients subsequently underwent serial echocardiography to assess for changes in valve hemodynamic performance (change in peak aortic velocity) and evidence of structural valve dysfunction. Comparisons were made with matched patients with bioprosthetic SAVR (n=51) who had undergone the same imaging protocol. RESULTS: In patients with TAVI, native aortic valves demonstrated 18F-NaF uptake around the outside of the bioprostheses that showed a modest correlation with the time from TAVI (r=0.36, P=0.023). 18F-NaF uptake in the bioprosthetic leaflets was comparable between the SAVR and TAVI groups (target-to-background ratio, 1.3 [1.2-1.7] versus 1.3 [1.2-1.5], respectively; P=0.27). The frequencies of imaging evidence of bioprosthetic valve degeneration at baseline were similar on echocardiography (6% versus 8%, respectively; P=0.78), computed tomography (15% versus 14%, respectively; P=0.87), and positron emission tomography (15% versus 29%, respectively; P=0.09). Baseline 18F-NaF uptake was associated with a subsequent change in peak aortic velocity for both TAVI (r=0.7, P<0.001) and SAVR (r=0.7, P<0.001). On multivariable analysis, 18F-NaF uptake was the only predictor of peak velocity progression (P<0.001). CONCLUSIONS: In patients with TAVI, native aortic valves demonstrate evidence of ongoing active disease. Across imaging modalities, TAVI degeneration is of similar magnitude to bioprosthetic SAVR, suggesting comparable midterm durability. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02304276.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Kwiecinski J, Tzolos E, Cartlidge TRG, et al. Native Aortic Valve Disease Progression and Bioprosthetic Valve Degeneration in Patients With Transcatheter Aortic Valve Implantation. Circulation. 2021. PMID: 34455857. doi:10.1161/CIRCULATIONAHA.121.056891

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。